Clinical Analysis Of Vinorelbine/Gemcitabine Versus Cisplatin/Gemcitabine In The Treatment Of Metastatic Breast Cancer

ObjectiveThe aim of this study is to evaluate the efficacy and safety between GN and GP regimen in the treatment of anthracycline and/or taxane-pretreated metastatic breast cancer, providing reference for eligible chemotherapy option after failure of anthracycline and/or taxane_treatment.MethodsFrom January2010to December2013,42patients with metastatic breast cancer, who had been previously treated with anthracyclines and/or taxanes were enrolled. They were treated with gemcitabine combined with vinorelbine or with cisplatin. Either treatment regimen was repeated every3weeks._The efficacy is evaluated every two cycles.ResultsThe overall response rate(ORR=CR+PR) of GN group was30.5%, disease control rate(DCR=CR+PR+SD) was78.3%,median time to progress(mTTP) was6months(95%CI4.6-7.3).In the GP group,ORR was33.3%,_DCR was77.8%,mTTP was5months(95%CI3.3-6.6). By subgroup analysis, the ORR of breast cancer with liver metastasis was7.7%in GN group, DCR was69.2%,In the GP group,_ORR was25.0%, DCR was75.0%.The ORR of breast cancer with lung metastasis was23.1%in GN group, DCR was76.9%, In the GP group,_ORR was11.1%,_DCR was66.7%.There was no statistical difference between the two group(P>0.05). No patient died due to chemotherapy. The main treatment-related toxicity in both groups was myelosuppression and gastrointestinal reactions.ConclusionGN and GP regimens are both effective in the treatment of anthracycline and/or taxane-pretreated metastatic breast cancer with acceptable toxicity. They both can be chosen for the treatment of anthracycline and/or taxane-pretreated metastatic breast cancer.